Status:
UNKNOWN
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
Lead Sponsor:
Herlev Hospital
Conditions:
Kidney Failure, Chronic
Cardiovascular Diseases
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether a combination therapy with angiotensin-converting enzyme (ACE)-inhibitors and angiotensin receptor blockers reduces the arterial stiffness assessed by...
Eligibility Criteria
Inclusion
- Creatinine: 150-350 micromol/L
- Blood pressure \> 110 systolic
- Negative pregnancy test for fertile women
- Written and oral informed consent from the patient
Exclusion
- Treatment with both ACE-inhibitors (ACE-I) and angiotensin receptor blockers
- Pregnancy or breastfeeding
- Treatment with immunosuppressive medication, steroids or non-steroidal anti-inflammatory drugs (NSAIDs)
- Serious chronic heart failure (New York Heart Association \[NYHA\] III-IV)
- Chronic liver disease
- Suspicion or verified kidney artery stenosis
- Cardiac arrhythmia and/or implanted pacemaker
- Myocardial infarction or cerebrovascular incidence within the last 3 months
- Allergy towards ACE-I or angiotensin receptor blockers
- Amputation of a whole extremity or the crural or femoral part of the leg
- Dementia or a psychological condition that makes understanding of the examination conditions impossible
- Dialysis or renal transplantation
- Treatment with aldosterone antagonists
- Hyperkalemia \> 5.5 mmol/l
- Another serious chronic non-renal disease
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00235287
Start Date
September 1 2005
Last Update
January 19 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Nephrology, Herlev University Hospital
Herlev, Denmark, 2730